The phytostanol analogue FM VP4*, a cholesterol absorption inhibitor, significantly lowered LDL-cholesterol levels,

2004 ◽  
Vol &NA; (1432-1433) ◽  
pp. 9
Author(s):  
&NA;
Keyword(s):  
Ldl Cholesterol ◽  
Cholesterol Absorption ◽  
Cholesterol Levels ◽  
Cholesterol Absorption Inhibitor

scholarly journals Korszerű lipidcsökkentő kezelés

2016 ◽  
Vol 157 (31) ◽  
pp. 1219-1223 ◽  
Author(s):  
György Paragh ◽  
István Karádi
Keyword(s):  
Monoclonal Antibodies ◽  
Cardiovascular Events ◽  
Ldl Cholesterol ◽  
Cholesterol Absorption ◽  
New Agents ◽  
Considerable Evidence ◽  
Cholesterol Levels ◽  
Cholesterol Absorption Inhibitor ◽  
Reasonable Approach ◽  
New Strategies

Considerable evidence suggests that “the lower the better” is a reasonable approach for reducing cardiovascular risk by lowering LDL cholesterol levels. Despite the reduction in cardiovascular events and mortality achieved by statin therapy, significant residual risk remains, especially in severe hereditary hypercholesterolemia, such as familial hypercholesterolemia. Some new strategies to achieve even lower LDL levels are now available, including the addition of cholesterol absorption inhibitor ezetimibe, and the recently available Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies. In addition, new LDL drugs may be effectively administrated in those individuals who are unable to tolerate statins. The authors summarize the efficacy and clinical indications of these new agents and review the currently available guidelines. Orv. Hetil., 2016, 157(31), 1219–1223.

Lipids in health and disease

2004 ◽  
Vol 32 (6) ◽  
pp. 1051-1056 ◽  
Author(s):  
J. Shepherd
Keyword(s):  
Statin Therapy ◽  
Poor Response ◽  
Cholesterol Absorption ◽  
Lipid Lowering ◽  
Cholesterol Lowering ◽  
Cholesterol Levels ◽  
Cholesterol Absorption Inhibitor ◽  
Health And Disease ◽  
Cholesterol Control ◽  
Lipid Lowering Agents

The evidence linking cholesterol levels in the blood to vascular risk is now incontrovertible and the introduction of HMG CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitor (or statin) therapy into clinical practice has now revolutionized the management of lipid disorders and silenced at a stroke the critics of cholesterol control as a means to vascular disease prevention. Statins were the first lipid-lowering agents, which, within a framework of a clinical trial, actually extended life by mechanisms that probably go beyond cholesterol alone. Their benefits are so impressive that some enthusiasts have been emboldened to write that they ‘are to atherosclerosis what penicillin was to infectious disease’. But is Nature as easily tamed as we might imagine? Some individuals show a modest or even poor response to statin therapy. The recent discovery of ezetimibe, a highly efficient and precise cholesterol absorption inhibitor, has proven to be a very effective cholesterol lowering alternative for them and combining statins with ezetimibe, thereby inhibiting cholesterol absorption and endogenous synthesis, takes us to realms of cholesterol lowering capability that could not have been dreamt of a decade ago.

scholarly journals Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels

2002 ◽  
Vol 88 (5) ◽  
pp. 479-488 ◽  
Author(s):  
Jacqueline de Graaf ◽  
Pernette R. W. de Sauvage Nolting ◽  
Marjel van Dam ◽  
Elizabeth M. Belsey ◽  
John J. P. Kastelein ◽  
...  
Keyword(s):  
Ldl Cholesterol ◽  
Controlled Trial ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Cholesterol Absorption ◽  
Tall Oil ◽  
Double Blind ◽  
Intestinal Cholesterol Absorption ◽  
Primary Hypercholesterolaemia ◽  
Cholesterol Levels

In a randomized, double-blind, placebo-controlled trial we evaluated the effect of dietary chocolates enriched with a wood-based phytosterol–phytostanol mixture, containing 18% (w/w) sitostanol, compared with placebo dietary chocolates in seventy subjects with primary hypercholesterolaemia (total cholesterol levels below 8 mmol/l). For 4 weeks, participants consumed three servings of the phytosterol-enriched chocolate/d that provided 1·8 g unesterified phytosterols/d or a placebo chocolate in conjunction with a low-fat, low-cholesterol diet. Plasma total and LDL-cholesterol levels were statistically significantly reduced by 6·4% (−0·44 mmol/l) and 10·3% (−0·49 mmol/l), respectively, after 4 weeks of phytosterol-enriched-chocolate treatment. Plasma HDL-cholesterol and triacylglycerol levels were not affected. Consumption of phytosterol-enriched chocolates significantly increased plasma lathosterol concentration (+20·7%), reflecting an increased endogenous cholesterol synthesis in response to phytosterol-induced decreased intestinal cholesterol absorption. Furthermore, the chocolates enriched with phytosterols significantly increased both plasma sitosterol (+95·8%) and campesterol (+64·1%) levels, compared with the placebo chocolate group. However, the absolute values of plasma sitosterol and campesterol remained within the normal range, that is, below 10 mg/l. The chocolates with phytosterols were palatable and induced no clinical or biochemical side effects. These findings indicate that dietary chocolate enriched with tall oil-derived phytosterols (1·8 g/d) is effective in lowering blood total and LDL-cholesterol levels in subjects with mild hypercholesterolaemia and thus may be helpful in reducing the risk of CHD in these individuals.

Ease: Ezetimibe Add-on to Statin for Effectiveness Trail

2006 ◽  
Vol 4 (1) ◽  
pp. 32-35
Author(s):  
Linda Brokes
Keyword(s):  
National Cholesterol Education Program ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cholesterol Absorption ◽  
Adult Treatment ◽  
Adult Treatment Panel ◽  
Community Based ◽  
Cholesterol Absorption Inhibitor ◽  
Additional Reduction

Results from the largest community-based clinical trial to date, involving more than 3000 patients, has shown that adding the cholesterol absorption inhibitor ezetimibe to ongoing stable statin therapy in patients with hypercholesterolemia produces a significant additional reduction in low-density lipoprotein (LDL)- cholesterol compared with adding a placebo.[1] In addition, more patients who added ezetimibe achieved their National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) If LDL-cholesterol targets. The Ezetimibe Add-on to Statin for Effectiveness (EASE) trial included a total of 3030 patients on a stable dose of a statin but not yet at their NCEP ATP III LDLcholesterel goal,[2]

The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 25 (30) ◽  
pp. 3266-3281 ◽  
Author(s):  
Hadis Fathizadeh ◽  
Alireza Milajerdi ◽  
Željko Reiner ◽  
Fariba Kolahdooz ◽  
Maryam Chamani ◽  
...  
Keyword(s):  
Serum Lipids ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Health Conditions ◽  
Carnitine Supplementation ◽  
Randomized Controlled ◽  
Cholesterol Levels ◽  
Vldl Cholesterol ◽  
Subgroup Analyses

Background: The findings of trials investigating the effects of L-carnitine administration on serum lipids are inconsistent. This meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effects of L-carnitine intake on serum lipids in patients and healthy individuals. Methods: Two authors independently searched electronic databases including MEDLINE, EMBASE, Cochrane Library, Web of Science, PubMed and Google Scholar from 1990 until August 1, 2019, in order to find relevant RCTs. The quality of selected RCTs was evaluated using the Cochrane Collaboration risk of bias tool. Cochrane’s Q test and I-square (I2) statistic were used to determine the heterogeneity across included trials. Weight mean difference (SMD) and 95% CI between the two intervention groups were used to determine pooled effect sizes. Subgroup analyses were performed to evaluate the source of heterogeneity based on suspected variables such as, participant’s health conditions, age, dosage of L-carnitine, duration of study, sample size, and study location between primary RCTs. Results: Out of 3460 potential papers selected based on keywords search, 67 studies met the inclusion criteria and were eligible for the meta-analysis. The pooled results indicated that L-carnitine administration led to a significant decrease in triglycerides (WMD: -10.35; 95% CI: -16.43, -4.27), total cholesterol (WMD: -9.47; 95% CI: - 13.23, -5.70) and LDL-cholesterol (LDL-C) concentrations (WMD: -6.25; 95% CI: -9.30, -3.21), and a significant increase in HDL-cholesterol (HDL-C) levels (WMD: 1.39; 95% CI: 0.21, 2.57). L-carnitine supplementation did not influence VLDL-cholesterol concentrations. When we stratified studies for the predefined factors such as dosage, and age, no significant effects of the intervention on triglycerides, LDL-C, and HDL-C levels were found. Conclusion: This meta-analysis demonstrated that L-carnitine administration significantly reduced triglycerides, total cholesterol and LDL-cholesterol levels, and significantly increased HDL-cholesterol levels in the pooled analyses, but did not affect VLDL-cholesterol levels; however, these findings were not confirmed in our subgroup analyses by participant’s health conditions, age, dosage of L-carnitine, duration of study, sample size, and study location.

Sign in / Sign up

Export Citation Format

Share Document